Choose your country to see the products for your location

SALSA MLPA Probemix P043 APC

Adenomatous polyposis, familial (FAP); MUTYH-associated polyposis (MAP); Polyposis syndrome, hereditary mixed (HMPS1)

Region: APC 5q22.2; MUTYH 1p34.1; GREM1 15q13.3

Intended use: The SALSA MLPA probemix P043 APC is an in vitro diagnostic (IVD)1 or a research use only (RUO) assay for the detection of deletions or duplications in the human APC gene, MUTYH gene, and the upstream region of the GREM1 gene, in order to confirm a potential cause and clinical diagnosis for familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), or hereditary mixed polyposis syndrome (HMPS1), respectively. In addition, the presence of the two most common point mutations in the MUTYH gene among Europeans can be detected by the P043 probemix. This product can also be used for molecular genetic testing of at-risk family members.

This assay is for use with human DNA extracted from peripheral blood and is not for use with DNA extracted from formalin-fixed paraffin embedded materials or fresh tumour material. Deletions or duplications detected with the P043 APC probemix should be verified by another technique. In particular, deletions or duplications detected by only a single probe always require validation by another method. Most defects in the APC and MUTYH gene are point mutations, the majority of which will not detected by MLPA, with exception of the two most common MUTYH mutations among Europeans. It is therefore recommended to use this SALSA MLPA probemix in combination with sequence analysis of these genes. In addition, there is a high incidence of mosaicism in FAP patients and mosaic APC mutations may not be detectable in blood or other healthy tissues. This assay is not intended to be used as a standalone assay for clinical decisions. The results of this test must be interpreted by a clinical molecular geneticist or equivalent.

Please note that this probemix is for In Vitro Diagnostic (IVD) use in the countries specified at the end of this product description. In all other countries, the product is for Research Use Only (RUO).

Clinical background: Germline defects in the APC gene are the most frequent cause of a hereditary predisposition to polyposis colon cancer, which can present as familial adenomatous polyposis (FAP), attenuated FAP (AFAP), or gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). In addition, mutations in the APC gene are an initiating event for sporadic colorectal tumour development. Most FAP patients develop adenomatous colonic polyps in the first two decades of life and in untreated individuals this progresses into colonic cancer at an average age of 39 years. APC-related colorectal cancer is a dominant trait. Approximately 4% of (A)FAP patients have a somatic mosaic APC mutation, which increases to ~20% when only de novo cases are considered. More information on APC-associated polyposis is available on

Mutations in the MUTYH gene result in a hereditary predisposition to colon and gastric cancer. In contrast to the APC gene, MUTYH-associated colorectal cancer is an autosomal recessive trait. Polyps caused by mutations in the MUTYH gene do not appear until adulthood and are less numerous than those found in patients with APC gene mutations. As the phenotypes of APC- and MUTYH-related colorectal cancer overlap, six probes for the MUTYH gene are included in this P043-E1 probemix, two of which will only generate a signal when the common c.536A>G (p.Tyr179Cys) or c.1187G>A (p.Gly396Asp) mutation is present; these two mutations account for ~80% of all MUTYH pathogenic variants among Europeans. Since the MUTYH gene is very small (11 kb), the four wildtype-specific probes are expected to detect a substantial part of MUTYH copy number changes. More information on MUTYH-associated polyposis is available on For complete exon coverage of MUTYH probemix P378 is available.

A recurrent duplication of 40 kb close to the GREM1 gene is known to be linked to an increased risk of developing colorectal cancer. This syndrome is known as hereditary mixed polyposis syndrome (HMPS1). Presence of this duplication is predicted to cause reduced bone morphogenetic protein (BMP) pathway activity, a mechanism that also underlies tumorigenesis in juvenile polyposis of the large bowel (Jaeger et al. 2012). Another duplication of ~16 kb in this region has been described more recently in members of a family presenting with atypical FAP (Rohlin et al. 2015). Furthermore, a duplication of the complete GREM1 gene, including the upstream region (~57 kb in total), has been described in one patient with sigmoid colon carcinoma (Venkatachalam et al. 2011). Two probes are included in the P043 probemix to detect the 40 kb and 57 kb duplications. The 16 kb duplication can be detected by one of these probes. More information on HMPS1 is available at

Among the various defects in the APC and MUTYH genes that have been found in patients, are deletions and duplications of complete exons, which are usually missed by standard sequence analysis. The MLPA technique can detect most of these deletions and duplications and therefore complements sequence analysis of the APC and MUTYH genes. It is expected that 6-12% of all APC mutations in most populations are large rearrangements that can be detected with this MLPA probemix (Kerr et al. 2013; Jarry et al. 2011). See ‘Selected publications’ below for relevant scientific articles on probemix P043 APC.

Probemix content: This SALSA MLPA probemix P043 APC contains 45 MLPA probes with amplification products between 130 and 483 nt: 29 probes for the APC gene, 6 probes for the MUTYH gene, 2 GREM1 upstream probes and 8 reference probes detecting autosomal chromosomes (Table 1 and Table 2). The identity of the genes detected by the reference probes is available online (

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity fragments (Q-fragments), two DNA Denaturation fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at

SALSA Binning DNA SD022: The SD022 Binning DNA provided with this probemix can be used for binning of the two mutation-specific probes in the MUTYH gene (probe 18416-SP0654-L29811, detecting the c.536A>G (p.Tyr179Cys) mutation; and probe 21267-SP0655-L23442, detecting the c.1187G>A (p.Gly396Asp) mutation). SD022 Binning DNA is a mixture of genomic DNA from healthy individuals and synthetic DNA that contains the target sequence detected by the above mentioned probes. Inclusion of one reaction with 5 μl SD022 Binning DNA in initial MLPA experiments is essential as it can be used to aid in data binning of the peak pattern using Coffalyser.Net software. Furthermore, Binning DNA should be included in the experiment whenever changes have been applied to the set-up of the capillary electrophoresis device (e.g. when capillaries have been renewed). Binning DNA should never be used as a positive reference in the MLPA data analysis, neither should it be used in quantification of mutation signals. For further details, please consult the SD022 Binning DNA product description, available online:

Sample DNA
Sample DNA developed for this product:

Order Items


Item no.
SALSA MLPA Probemix P043 APC – 25 rxn
€ 243.00
SALSA MLPA Probemix P043 APC – 50 rxn
€ 486.00
SALSA MLPA Probemix P043 APC – 100 rxn
€ 972.00

Required Reagents

Item no.
SALSA MLPA EK1 reagent kit – 100 rxn – FAM
€ 300.00
SALSA MLPA EK1 reagent kit – 100 rxn – Cy5
€ 300.00
SALSA MLPA EK5 reagent kit – 500 rxn – FAM
€ 1380.00
SALSA MLPA EK5 reagent kit – 500 rxn – Cy5
€ 1380.00
SALSA MLPA EK20 reagent kit – 2000 rxn – FAM
€ 5295.00

Related Products

Improved Nov 03, 2020

SALSA MLPA Probemix ME011 Mismatch Repair Genes

Contains MS-MLPA probes for promoter regions of MLH1, MSH2, MSH6 and PMS2 genes.


Contains 31 MS-MLPA targeting the promoter regions of the CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1 genes.

SALSA MLPA Probemix P003 MLH1/MSH2

Lynch syndrome: Contains probes for MLH1 and MSH2.

SALSA MLPA Probemix P008 PMS2

Lynch syndrome: Contains probes for PMS2.


Contains probes for MSH6, MUTYH and EPCAM.

SALSA MLPA Probemix P248 MLH1-MSH2 Confirmation

Results obtained with P003 (MLH1 and MSH2) can be confirmed with this probemix.


Contains probes for MUTYH, SCG5 and GREM1.

Sign in

Don't have an account? Create one

Forgot password?

Select Your Country

Choose your country to see the products for your location


One HhaI digestion control probe replaced,four reference probes removed,one SNP-specific probe added


CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA).


IVD-registered in Israel.


IVD-registered in Morocco.